The IMPACT trial: Stopping the immune system from attacking insulin-producing cells

One key area of research for slowing and preventing the onset of type 1 diabetes (T1D) is understanding how to stop the immune system from attacking and destroying the cells in the pancreas that produce insulin.  

What is the IMPACT Trial? 

A new JDRF-funded study, known as the IMPACT trial, is testing if a new and experimental drug IMCY-0098 can help in this process.  

The study is designed to determine if IMCY-0098 (which is injected) will trigger the production of new immune cells that can target and destroy the cells that damage the pancreas, intercepting the process before the body’s ability to produce insulin is impacted. 

IMCY-0098 was found to be safe when tested on people recently diagnosed with T1D in its first clinical study, and the current trial is running to understand the most effective and efficient way to offer the treatment to people in the community.  

How can I get involved and learn more about the trial? 

The study is open to people between 18 and 45 years of age who meet specific requirements, including a recent T1D diagnosis (i.e., are within 9-weeks from their first administration of insulin). Trial sites are currently operating in Melbourne, and sites in Sydney and Brisbane will also be available in the coming months.  

For more information about the trial, you can visit https://type1screen.org/trial-for-new-t1d-diagnosis/ or view the video.

If you think you may be eligible for this trial and are interested in participating, please email the study team at: type1screen@mh.org.au 

This trial is a collaboration between Imcyse and INNODIA, supported by JDRF funding.